Increased serum concentrations of YKL-40 were observed in patients affected by pathologies involving extracellular matrix degradation and angiogenesis, such as rheumatoid arthritis [22], hepatic fibrosis [23], and osteoarthritis [24], as well as cancer [1]. Here, CHI3L1 is linked to rheumatoid arthritis.